About GZ Sanli
GZ Sanli is a publicly listed company founded in 1995. The company has 2,850 employees. GZ Sanli offers products and services including Pediatric Drugs and Respiratory Drugs. Its focus areas include Alternative Medicine Products. Its legal entity in India is θ΄΅ε·δΈεεΆθ―θ‘δ»½ζιε ¬εΈ (U99999MH1977PLC010754).
Company details
Manufacturer of traditional Chinese medicine pharmaceuticals. It focuses on pediatric, respiratory, cardiovascular, and digestive internal medicine areas. The company integrates cultivation, research, production, and marketing. A key focus is on developing high-quality drugs with significant therapeutic advantages, particularly for critical illnesses. The company adheres to stringent quality standards and has received numerous industry recognitions. Its commitment is to advancing traditional Chinese medicine through modern techniques while maintaining a focus on patient needs.
- Employees 2,850
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website gz-sanli.com
- Legal Name Guizhou Sanli Pharmaceutical Co., Ltd. Class A
- Annual Revenue$241.39 M (USD)-20.65as on Dec 31, 2025
- Net Profit$6.61 M (USD)-83.12as on Dec 31, 2025
- EBITDA$37.43 M (USD)-34.56as on Dec 31, 2025
- Investors
- Employee Count2,850
Associated legal entities of GZ Sanli
GZ Sanli operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of GZ Sanli
GZ Sanli offers a comprehensive portfolio of products and services, including Pediatric Drugs and Respiratory Drugs.
Drugs for pediatric use are manufactured and marketed to address child health needs, drawing from traditional Chinese medicine practices
Drugs for respiratory systems are developed and produced to treat related conditions, incorporating modern research methodologies
Funding Insights of GZ Sanli
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of GZ Sanli with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | Unspecified | β | Cowin Capital | β |
1 investors in total: 1 institutional.
Investors in GZ Sanli
GZ Sanli has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Cowin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| cowincapital.com.cn |
Investor details for GZ Sanli
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of GZ Sanli
GZ Sanli is a publicly listed company on the SSE with ticker symbol 603439 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Apr 2020
- Listed onSSE: 603439
- Listed entityGuiZhou SanLi Pharmaceutical Co., Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE1000040B4
- Share price11.22 CNY (-1.23% on the day) · 2026-10-14
- Market capitalisation4,587,624,647.00 CNY
- Price to earnings5,905.3
- EPS (diluted, trailing year)0.00 CNY
- Dividend yield0.53%
- Volume (last session)14,740,500
Financials of GZ Sanli
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.69B CNY | 46.2M CNY | 262.1M CNY |
| 2024 | 2.13B CNY | 274.0M CNY | 400.5M CNY |
| 2023 | 1.62B CNY | 292.7M CNY | 307.0M CNY |
| 2022 | 1.19B CNY | 201.3M CNY | 222.3M CNY |
| 2021 | 932.3M CNY | 152.3M CNY | 163.1M CNY |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for GZ Sanli
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GZ Sanli
3 dated milestones of GZ Sanli across 25 years, from founding to its latest funding, stage changes and deals.
- Founded GZ Sanli is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gz Sanli
Complete news archive for GZ Sanli
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GZ Sanli
GZ Sanli was founded in 1995 and raised its 1st funding round 21 years after it was founded.
GZ Sanli has 2,850 employees.
Annual revenue of GZ Sanli is $241.39M as on Dec 31, 2025.
Manufacturer of traditional Chinese medicine pharmaceuticals. It focuses on pediatric, respiratory, cardiovascular, and digestive internal medicine areas. The company integrates cultivation, research, production, and marketing. A key focus is on developing high-quality drugs with significant therapeutic advantages, particularly for critical illnesses. The company adheres to stringent quality standards and has received numerous industry recognitions. Its commitment is to advancing traditional Chinese medicine through modern techniques while maintaining a focus on patient needs.
GZ Sanli offers Pediatric Drugs and Respiratory Drugs.
Yes, GZ Sanli is publicly traded on SSE under the ticker symbol 603439.
GZ Sanli has 1 investor. Key investors include Cowin Capital.
GZ Sanli operates through ,.